-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-519331-42-00
5
2025-08-22
pMMR endometrial carcinoma
-
2024-517972-39-00
5
2025-08-19
Autoimmune haemolytic anaemia
-
2024-516337-12-00
5
2025-08-07
Knee osteoarthritis with moderate to severe pain
-
2024-519688-16-00
4
2025-08-07
venous thromboembolism
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2023-503184-42-00
6
2025-07-28
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
-
2024-519291-11-00
4
2025-07-25
Psoriatic Arthritis
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-519059-28-00
5
2025-07-17
Chronic Heart Failure
-
2024-516834-36-00
5
2025-07-08
Locally recurrent unresectable or metastatic TNBC with tumors expressi
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-516020-33-00
4
2025-06-26
Grave’s Disease
-
2024-517335-46-00
4
2025-06-05
Bladder cancer
-
2024-517457-27-00
5
2025-06-04
Chronic Obstructive Pulmonary Disease (COPD)
-
2024-515280-60-00
5
2025-05-29
Lupus nephritis
-
2024-519116-14-00
4
2025-05-27
Asthma
-
2023-509547-27-00
5
2025-05-22
Geographic Atrophy Secondary to Age-Related Macular Degeneration
-
2024-517513-32-00
5
2025-05-16
Sjögren’s Syndrome
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-516009-22-00
5
2025-04-30
myelodysplastic neoplasms/syndromes (MDS)
-
2024-517284-23-00
5
2025-04-23
Active Psoriatic Arthritis
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma